77 related articles for article (PubMed ID: 17651033)
1. Viracept contaminated in Europe.
AIDS Patient Care STDS; 2007 Jul; 21(7):521. PubMed ID: 17651033
[No Abstract] [Full Text] [Related]
2. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
3. European license for Viracept re-established by EC.
AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338433
[No Abstract] [Full Text] [Related]
4. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
5. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
6. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
7. The Viracept-EMS case: impact and outlook.
Walker VE; Casciano DA; Tweats DJ
Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
[TBL] [Abstract][Full Text] [Related]
8. Viracept recommended for reinstatement in Europe.
AIDS Patient Care STDS; 2007 Oct; 21(10):780. PubMed ID: 17992722
[No Abstract] [Full Text] [Related]
9. Recall of AIDS drug hits world's poorest patients.
AIDS Read; 2007 Sep; 17(9):439. PubMed ID: 17902224
[No Abstract] [Full Text] [Related]
10. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
11. Nelfinavir (Viracept) price increase 4.6 percent.
AIDS Treat News; 1998 Oct; (No 305):3-4. PubMed ID: 11365867
[TBL] [Abstract][Full Text] [Related]
12. Women's nelfinavir (Viracept) trial.
Vazquez E
Posit Aware; 1997; 8(5):15. PubMed ID: 11364633
[TBL] [Abstract][Full Text] [Related]
13. Ultrase and Viracept.
Fornataro K; Jefferys R
Body Posit; 1999 Oct; 12(10):10. PubMed ID: 11366873
[TBL] [Abstract][Full Text] [Related]
14. Nelfinavir (Viracept).
Res Initiat Treat Action; 2000 Mar; 6(1):30-1. PubMed ID: 11708185
[No Abstract] [Full Text] [Related]
15. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
[TBL] [Abstract][Full Text] [Related]
16. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
17. Nelfinavir (Viracept) moves up the ranks.
Grodeck B
Posit Aware; 1997; 8(2):16-7. PubMed ID: 11364452
[TBL] [Abstract][Full Text] [Related]
18. Nelfinavir (Viracept) approved: fourth protease inhibitor available.
James JS
AIDS Treat News; 1997 Mar; (No 267):1-2. PubMed ID: 11364249
[TBL] [Abstract][Full Text] [Related]
19. Nelfinavir: fourth protease inhibitor approved.
Crit Path AIDS Proj; 1997; (No 32):31-2. PubMed ID: 11364442
[TBL] [Abstract][Full Text] [Related]
20. Viracept and irregular heartbeat warning.
Fornataro K; Jefferys R
Body Posit; 1999 Oct; 12(10):10, 12. PubMed ID: 11366874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
